A current clinical overview of atrophic gastritis

References

• Rugge M, Correa P, Dixon MF, et al. Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Aliment Pharmacol Ther. 2002;16:1249–1259.
   PubMed Web of Science ®Google Scholar
• Varbanova M, Frauenschläger K, Malfertheiner P. Chronic gastritis - an update. Best Pract Res Clin Gastroenterol. 2014;28:1031–1042.
   PubMed Web of Science ®Google Scholar
• Neumann WL, Coss E, Rugge M, et al. Autoimmune atrophic gastritis–pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol. 2013;10:529–541.
   PubMed Web of Science ®Google Scholar
• Weck MN, Brenner H. Prevalence of chronic atrophic gastritis in different parts of the world. Cancer Epidemiol Biomark Prev. 2006;15: 1083–1094. Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol.
   PubMed Web of Science ®Google Scholar
• Sipponen P, Laxén F, Huotari K, et al. Prevalence of low vitamin B12 and high homocysteine in serum in an elderly male population: association with atrophic gastritis and Helicobacter pylori infection. Scand J Gastroenterol. 2003;38:1209–1216.
   PubMed Web of Science ®Google Scholar
• Zou D, He J, Ma X, et al. Helicobacter pylori infection and gastritis: the systematic investigation of gastrointestinal diseases in China [SILC]. J Gastroenterol Hepatol. 2011;26:908–915.
   PubMed Web of Science ®Google Scholar
• Marques-Silva L, Areia M, Elvas L, et al. Prevalence of gastric precancerous conditions: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2014;26:378–387.
   PubMed Web of Science ®Google Scholar
• Adamu MA, Weck MN, Gao L, et al. Incidence of chronic atrophic gastritis: systematic review and meta-analysis of follow-up studies. Eur J Epidemiol. 2010;25:439–448.
   PubMed Web of Science ®Google Scholar
• D’Elios MM, Bergman MP, Azzurri A, et al. H[+],K[+]-atpase [proton pump] is the target autoantigen of Th1-type cytotoxic T cells in autoimmune gastritis. Gastroenterology. 2001;120:377–386.
   PubMed Web of Science ®Google Scholar
• Toh BH, Sentry JW, Alderuccio F. The causative H+/K+ ATPase antigen in the pathogenesis of autoimmune gastritis. Immunol Today. 2000;21:348–354.
   PubMedGoogle Scholar
• Correa P. The biological model of gastric carcinogenesis. IARC Sci Publ. 2004;157:301–310.
   PubMedGoogle Scholar
• Correa P, Haenszel W, Cuello C, et al. Gastric precancerous process in a high risk population: cohort follow-up. Cancer Res. 1990;50:4737–4740.
   PubMed Web of Science ®Google Scholar
• Villako K, Kekki M, Maaroos HI, et al. Chronic gastritis: progression of inflammation and atrophy in a six-year endoscopic follow-up of a random sample of 142 Estonian urban subjects. Scand J Gastroenterol. 1991;26:135–141.
   Web of Science ®Google Scholar
• Kuipers EJ, Uyterlinde AM, Peña AS, et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet. 1995;345:1525–1528.
   PubMed Web of Science ®Google Scholar
• Vannella L, Lahner E, Bordi C, et al. Reversal of atrophic body gastritis after H. pylori eradication at long-term follow-up. Dig Liver Dis. 2011;43:295–299.
   PubMedGoogle Scholar
• Rokkas T, Pistiolas D, Sechopoulos P, et al. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis. Helicobacter. 2007;12(Suppl 2):32–38.
   PubMed Web of Science ®Google Scholar
• Delle Fave G, Kwekkeboom DJ, Van Cutsem E, et al. Barcelona consensus conference participants. ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology. 2012;95:74–87.
   PubMed Web of Science ®Google Scholar
• Hershko C, Ronson A, Souroujon M, et al. Variable hematologic presentation of autoimmune gastritis: age-related progression from iron deficiency to cobalamin depletion. Blood. 2006;107:1673–1679.
   PubMed Web of Science ®Google Scholar
• Marignani M, Delle Fave G, Mecarocci S, et al. High prevalence of atrophic body gastritis in patients with unexplained microcytic and macrocytic anemia: a prospective screening study. Am J Gastroenterol. 1999;94:766–772.
   PubMed Web of Science ®Google Scholar
• Lahner E, Centanni M, Agnello G, et al. Occurrence and risk factors for autoimmune thyroid disease in patients with atrophic body gastritis. Am J Med. 2008;121:136–141.
   PubMed Web of Science ®Google Scholar
• De Block CE, De Leeuw IH, Van Gaal LF. Autoimmune gastritis in type 1 diabetes: a clinically oriented review. J Clin Endocrinol Metab. 2008;93:363–371.
   PubMed Web of Science ®Google Scholar
• Lahner E, Carabotti M, Annibale B. Atrophic body gastritis: clinical presentation, diagnosis, and outcome. EMJ Gastroenterol. 2017;6:75–82.
   Google Scholar
• Miceli E, Lenti MV, Padula D, et al. Common features of patients with autoimmune atrophic gastritis. Clin Gastroenterol Hepatol. 2012;10:812–814.
   PubMed Web of Science ®Google Scholar
• Lahner E, Carabotti M, Esposito G, et al. Occurrence and predictors of metaplastic atrophic gastritis in a nation-wide consecutive endoscopic population presenting with upper gastrointestinal symptoms. Eur J Gastroenterol Hepatol. 2018;30:1291–1296.
   PubMed Web of Science ®Google Scholar
• Lahner E, Zagari RM, Zullo A, et al. Chronic atrophic gastritis: natural history, diagnosis and therapeutic management. A position paper by the Italian Society of Hospital Gastroenterologists and Digestive Endoscopists [AIGO], the Italian Society of Digestive Endoscopy [SIED], the Italian Society of Gastroenterology [SIGE], and the Italian Society of Internal Medicine [SIMI]. Dig Liver Dis. 2019;51:1621–1632.
   PubMedGoogle Scholar
• Weck MN, Stegmaier C, Rothenbacher D, et al. Epidemiology of chronic atrophic gastritis: population-based study among 9444 older adults from Germany. Aliment Pharmacol Ther. 2007;26:879–887.
   PubMed Web of Science ®Google Scholar
• Roman LD, Lukyanchuk R, Sablin OA, et al. Prevalence of H. pylori infection and atrophic gastritis in a population-based screening with serum biomarker panel [GastroPanel®] in St. Petersburg. Anticancer Res. 2016;36:4129–4138.
   PubMed Web of Science ®Google Scholar
• de Vries AC, Meijer GA, Looman CW, et al. Epidemiological trends of pre‐malignant gastric lesions: a long-term nationwide study in the Netherlands. Gut. 2007;56:1665–1670.
   PubMed Web of Science ®Google Scholar
• Song H, Held M, Sandin S, et al. Increase in the prevalence of atrophic gastritis among adults age 35 to 44 years old in northern sweden between 1990 and 2009. Clin Gastroenterol Hepatol. 2015;13:1592–1600.e1.
   PubMed Web of Science ®Google Scholar
• Lenti MV, Miceli E, Cococcia S, et al. Determinants of diagnostic delay in autoimmune atrophic gastritis. Aliment Pharmacol Ther. 2019;50:167–175.
   PubMed Web of Science ®Google Scholar
• Lahner E, Annibale B. Pernicious anemia: new insights from a gastroenterological point of view. World J Gastroenterol. 2009;15:5121–5128.
   PubMed Web of Science ®Google Scholar
• Hershko C, Hoffbrand AV, Keret D, et al. Role of autoimmune gastritis, Helicobacter pylori and celiac disease in refractory or unexplained iron deficiency anemia. Haematologica. 2005;90:585–595.
   PubMed Web of Science ®Google Scholar
• Annibale B, Capurso G, Chistolini A, et al. Gastrointestinal causes of refractory iron deficiency anemia in patients without gastrointestinal symptoms. Am J Med. 2001;111:439–445.
   PubMed Web of Science ®Google Scholar
• Lachner C, Steinle NI, Regenold WT, et al. The neuropsychiatry of vitamin B12 deficiency in elderly patients. J Neuropsychiatry Clin Neurosci. 2012;24:5–15.
   PubMed Web of Science ®Google Scholar
• Couriel DR, Ricker H, Steinbach M, et al. Neurologic manifestations of blood dyscrasias. Hematol Oncol Clin North Am. 2016;30:723–731.
   PubMed Web of Science ®Google Scholar
• Yang GT, Zhao HY, Kong Y, et al. Correlation between serum vitamin B12 level and peripheral neuropathy in atrophic gastritis. World J Gastroenterol. 2018;24:1343–1352.
   PubMed Web of Science ®Google Scholar
• Jáuregui-Lobera I. Iron deficiency and cognitive functions. Neuropsychiatr Dis Treat. 2014;10:2087–2095.
   PubMed Web of Science ®Google Scholar
• Santarelli L, Gabrielli M, Cremonini F, et al. Atrophic gastritis as a cause of hyperhomocysteinaemia. Aliment Pharmacol Ther. 2004;19:107–111.
   PubMed Web of Science ®Google Scholar
• Ammouri W, Mezalek Tazi Z, Harmouche H, et al. Venous thromboembolism and hyperhomocysteinemia as first manifestation of pernicious anemia: a case series. J Med Case Rep. 2017;11:250.
   PubMedGoogle Scholar
• Venkatesh P, Shaikh N, Malmstrom MF, et al. Portal, superior mesenteric and splenic vein thrombosis secondary to hyperhomocysteinemia with pernicious anemia: a case report. J Med Case Rep. 2014;8:286.
   PubMedGoogle Scholar
• Fernández-Miranda C, Yebra Yebra M, Ribera Casado C, et al. Venous thromboembolism and hyperhomocysteinemia as first manifestation of pernicious anemia. Rev Clin Esp. 2005;205:489–492.
   PubMed Web of Science ®Google Scholar
• Carabotti M, Lahner E, Esposito G, et al. Upper gastrointestinal symptoms in autoimmune gastritis: a crosssectional study. Med [Baltimore]. 2017;96:e5784.
   PubMed Web of Science ®Google Scholar
• Tenca A, Massironi S, Pugliese D, et al. Gastro-esophageal reflux and antisecretory drugs use among patients with chronic autoimmune atrophic gastritis: a study with pH-impedance monitoring. Neurogastroenterol Motil. 2016;28:274–280.
   PubMed Web of Science ®Google Scholar
• Carabotti M, Esposito G, Lahner E, et al. Gastroesophageal reflux symptoms and microscopic esophagitis in a cohort of consecutive patients affected by atrophic body gastritis: a pilot study. Scand J Gastroenterol. 2019;13:1–6.
   Google Scholar
• Moayyedi PM, Lacy BE, Andrews CN, et al. ACG and CAG clinical guideline: management of dyspepsia. Am J Gastroenterol. 2017;112:988–1013.
   PubMed Web of Science ®Google Scholar
• El-Omar EM, Oien K, Murray LS, et al. Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H. pylori. Gastroenterology. 2000;118:22–30.
   PubMed Web of Science ®Google Scholar
• Chang YW, Han YS, Lee DK, et al. Role of Helicobacter pylori infection among offspring or siblings of gastric cancer patients. Int J Cancer. 2002;101:469–474.
   PubMed Web of Science ®Google Scholar
• Oh S, Kim N, Yoon H, et al. Risk factors of atrophic gastritis and intestinal metaplasia in first-degree relatives of gastric cancer patients compared with age-sex matched controls. J Cancer Prev. 2013;18:149–160.
   PubMedGoogle Scholar
• Motta CR, Cunha MP, Queiroz DM, et al. Gastric precancerous lesions and Helicobacter pylori infection in relatives of gastric cancer patients from Northeastern Brazil. Digestion. 2008;78:3–8.
   PubMed Web of Science ®Google Scholar
• Romiti A, Zullo A, Tomao S, et al. Gastric mucosa alterations in first-degree relatives of gastric cancer patients. Anticancer Res. 2005;25:2567–2572.
   PubMed Web of Science ®Google Scholar
• The Eurohepygast Study Group. Risk factors for atrophic chronic gastritis in a European population: results of the Eurohepygast study. Gut. 2002;50:779–785.
   PubMed Web of Science ®Google Scholar
• Rokkas T, Sechopoulos P, Pistiolas D, et al. Helicobacter pylori infection and gastric histology in first-degree relatives of gastric cancer patients: A meta-analysis. Eur J Gastroenterol Hepatol. 2010;22:1128–1133.
   PubMed Web of Science ®Google Scholar
• Song H, Ekheden IG, Ploner A, et al. Family history of gastric mucosal abnormality and the risk of gastric cancer: a population-based observational study. Int J Epidemiol. 2018;47:440–449.
   PubMed Web of Science ®Google Scholar
• Nishizawa T, Suzuki H, Sakitani K, et al. Family history is an independent risk factor for the progression of gastric atrophy among patients with Helicobacter pylori infection. United European Gastroenterol J. 2017;5:32–36.
   PubMed Web of Science ®Google Scholar
• Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med. 1996;334:1018–1022.
   PubMed Web of Science ®Google Scholar
• Geboes K, Dekker W, Mulder CJ, et al. Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa. Aliment Pharmacol Ther. 2001;15:1819–1826.
   PubMed Web of Science ®Google Scholar
• García Rodríguez LA, Lagergren J, Lindblad M, et al. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut. 2006;55:1538–1544.
   PubMed Web of Science ®Google Scholar
• Li Z, Wu C, Li L, et al. Effect of long-term proton pump inhibitor administration on gastric mucosal atrophy: A meta-analysis. Saudi J Gastroenterol. 2017;23:222–228.
   PubMed Web of Science ®Google Scholar
• Kamada T, Haruma K, Ito M, et al. Time trends in Helicobacter pylori infection and atrophic gastritis over 40 years in Japan. Helicobacter. 2015;20:192–198.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Haruma K, Kamada T, et al. Cigarette smoking promotes atrophic gastritis in Helicobacter pylori-positive subjects. Dig Dis Sci. 2002;47:675–681.
   PubMed Web of Science ®Google Scholar
• Shikata K, Kiyohara Y, Kubo M, et al. A prospective study of dietary salt intake and gastric cancer incidence in a defined Japanese population: the Hisayama study. Int J Cancer. 2006;119:196–201.
   PubMed Web of Science ®Google Scholar
• Thapa S, Fischbach LA, Delongchamp R, et al. Association between dietary salt intake and progression in the gastric precancerous process. Cancers (Basel). 2019 Apr 3;11(4):E467..
   PubMed Web of Science ®Google Scholar
• Song JH, Kim YS, Heo NJ, et al. High salt intake is associated with atrophic gastritis with intestinal metaplasia. Cancer Epidemiol Biomarkers Prev. 2017;26:1133–1138.
   PubMed Web of Science ®Google Scholar
• Nieminen AA, Kontto J, Puolakkainen P, et al. Long-term gastric cancer risk in male smokers with atrophic corpus gastritis. Scand J Gastroenterol. 2019;54:145–151.
   PubMed Web of Science ®Google Scholar
• Kim K, Chang Y, Ahn J, et al. Body mass index and risk of intestinal metaplasia: a cohort study. Cancer Epidemiol Biomarkers Prev. 2019;28:789–797.
   PubMed Web of Science ®Google Scholar
• Hirabayashi M, Inoue M, Sawada N, et al. Effect of body-mass index on the risk of gastric cancer: A population-based cohort study in A Japanese population. Cancer Epidemiol. 2019;63:101622.
   PubMed Web of Science ®Google Scholar
• Massironi S, Zilli A, Elvevi A, et al. The changing face of chronic autoimmune atrophic gastritis: an updated comprehensive perspective. Autoimmun Rev. 2019;18:215–222.
   PubMed Web of Science ®Google Scholar
• Kalkan C, Soykan I. Polyautoimmunity in autoimmune gastritis. Eur J Int Med. 2016;31:79–83.
   PubMed Web of Science ®Google Scholar
• Centanni M, Marignani M, Gargano L, et al. Atrophic body gastritis in patients with autoimmune thyroid disease: an underdiagnosed association. Arch Intern Med. 1999;159:1726–1730.
   PubMedGoogle Scholar
• Cellini M, Santaguida MG, Virili C, et al. Hashimoto’s thyroiditis and autoimmune gastritis. Front Endocrinol [Lausanne]. 2017;8:92.
   PubMed Web of Science ®Google Scholar
• Tozzoli R, Kodermaz G, Perosa AR, et al. Autoantibodies to parietal cells as predictors of atrophic body gastritis: a five-year prospective study in patients with autoimmune thyroid diseases. Autoimmun Rev. 2010;10:80–83.
   PubMed Web of Science ®Google Scholar
• Utiyama SRR, De Bem RS, Skare TL, et al. Anti-parietal cell antibodies in patients with autoimmune thyroid diseases. J Endocrinol Invest. 2018;41:523–529.
   PubMed Web of Science ®Google Scholar
• De Block CE, De Leeuw IH, Bogers JJ, et al. Autoimmune gastropathy in type 1 diabetic patients with parietal cell antibodies: histological and clinical findings. Diabetes Care. 2003;26:82–88.
   PubMed Web of Science ®Google Scholar
• Kahaly GJ, Hansen MP. Type 1 diabetes associated autoimmunity. Autoimmun Rev. 2016;15:644–648.
   PubMed Web of Science ®Google Scholar
• Kozhakhmetova A, Wyatt RC, Caygill C, et al. A quarter of patients with type 1 diabetes have co-existing non-islet autoimmunity: the findings of a UK population-based family study. Clin Exp Immunol. 2018;192:251–258.
   PubMed Web of Science ®Google Scholar
• Fichna M, Fichna P, Gryczyńska M, et al. Screening for associated autoimmune disorders in polish patients with Addison’s disease. Endocrine. 2010;37:349–360.
   PubMed Web of Science ®Google Scholar
• Sawicki J, Siddha S, Rosen C. Vitiligo and associated autoimmune disease: retrospective review of 300 patients. J Cutan Med Surg. 2012;16:261–266.
   PubMed Web of Science ®Google Scholar
• Kimura K, Satoh K, Ido K, et al. Gastritis in the Japanese stomach. Scand J Gastroenterol Suppl. 1996;214:17–20.
   PubMedGoogle Scholar
• Sugano K, Tack J, Kuipers E, et al. faculty members of kyoto global consensus conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64:1353–1367.
   PubMed Web of Science ®Google Scholar
• Pimentel-Nunes P, Libânio D, Marcos-Pinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach [MAPS II]: european Society of Gastrointestinal Endoscopy [ESGE], European Helicobacter and Microbiota Study Group [EHMSG], European Society of Pathology [ESP], and Sociedade Portuguesa de Endoscopia Digestiva [SPED] guideline update 2019. Endoscopy. 2019;51:365–388.
   PubMed Web of Science ®Google Scholar
• Mastracci L, Bruno S, Spaggiari S, et al. The impact of biopsy number and site on the accuracy of intestinal metaplasia detection in the stomach. A morphometric study based on virtual biopsies. Dig Liver Dis. 2008;40:632–640.
   PubMedGoogle Scholar
• Capelle LG, de Vries AC, Haringsma J, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc. 2010;71:1150–1158.
   PubMed Web of Science ®Google Scholar
• Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis: the updated Sydney system. Am J Surg Pathol. 1996;20:1161–1181.
   PubMed Web of Science ®Google Scholar
• Zullo A, Hassan C, Repici A, et al. Intestinal metaplasia surveillance: searching for the roadmap. World J Gastroenterol. 2013;19:1523–1526.
   PubMed Web of Science ®Google Scholar
• Rugge M, Correa P, Di Mario F, et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis. 2008;40:650–658.
   PubMedGoogle Scholar
• de Vries AC, Haringsma J, de Vries RA, et al. Biopsy strategies for endoscopic surveillance of pre-malignant gastric lesions. Helicobacter. 2010;15:259.
   PubMed Web of Science ®Google Scholar
• Bisschops R, Areia M, Coron E, et al. Performance measures for upper gastrointestinal endoscopy: A European society of gastrointestinal endoscopy quality improvement initiative. United European Gastroenterol J. 2016;4:629–656.
   PubMed Web of Science ®Google Scholar
• Beg S, Ragunath K, Wyman A, et al. Quality standards in upper gastrointestinal endoscopy: a position statement of the British Society of Gastroenterology (BSG) and Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland (AUGIS). Gut. 2017;66:1886–1899.
   PubMed Web of Science ®Google Scholar
• Barbeiro S, Libânio D, Castro R, et al. Narrow-band imaging: clinical application in gastrointestinal endoscopy. GE Port J Gastroenterol. 2018;26:40–53.
   PubMedGoogle Scholar
• Kikuste I, Marques-Pereira R, Monteiro-Soares M, et al. Systematic review of the diagnosis of gastric premalignant conditions and neoplasia with high-resolution endoscopic technologies. Scand J Gastroenterol. 2013;48:1108–1117.
   PubMed Web of Science ®Google Scholar
• Pimentel-Nunes P, Libânio D, Lage J, et al. A multicenter prospective study of the real-time use of narrow-band imaging in the diagnosis of premalignant gastric conditions and lesions. Endoscopy. 2016;48:723–730.
   PubMed Web of Science ®Google Scholar
• Esposito G, Pimentel-Nunes P, Angeletti S, et al. Endoscopic grading of gastric intestinal metaplasia [EGGIM]: a multicenter validation study. Endoscopy. 2019;51:515–521.
   PubMedGoogle Scholar
• Castro R, Esposito G, Libânio D, et al. A single vial is enough in the absence of endoscopic suspected intestinal metaplasia - less is more!. Scand J Gastroenterol. 2019;54:673–677.
   PubMed Web of Science ®Google Scholar
• Castro R, Rodriguez M, Libânio D, et al. Reliability and accuracy of blue light imaging for staging of intestinal metaplasia in the stomach. Scand J Gastroenterol. 2019;54:1301–1305.
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection – the maastricht v/florence consensus report. Gut. 2017;66:6–30.
   PubMed Web of Science ®Google Scholar
• Agréus L, Kuipers EJ, Kupcinskas L, et al. Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scand J Gastroenterol. 2012;47:136–147.
   PubMed Web of Science ®Google Scholar
• Huang YK, Yu JC, Kang WM, et al. Significance of serum pepsinogens as a biomarker for gastric cancer and atrophic gastritis screening: a systematic review and meta-analysis. PLOS One. 2015;10:1–23.
   Web of Science ®Google Scholar
• Leja M, Camargo MC, Polaka I, et al. Detection of gastric atrophy by circulating pepsinogens: a comparison of three assays. Helicobacter. 2017;22:1–12.
   Web of Science ®Google Scholar
• Wang X, Ling L, Li S, et al. The diagnostic value of gastrin-17 detection in atrophic gastritis. A meta-analysis. Medicine (Baltimore). 2016;95:1–9.
   Web of Science ®Google Scholar
• Venerito M, Varbanova M, Röhl FW, et al. Oxyntic gastric atrophy in Helicobacter pylori gastritis is distinct from autoimmune gastritis. J Clin Pathol. 2016;69:677–685.
   PubMed Web of Science ®Google Scholar
• Zagari RM, Rabitti S, Greenwood DC, et al. Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis. Aliment Pharmacol Ther. 2017;46:657–667.
   PubMed Web of Science ®Google Scholar
• De Re V, Orzes E, Canzonieri V, et al. Pepsinogens to distinguish patients with gastric intestinal metaplasia and Helicobacter pylori infection among populations at risk for gastric cancer. Clin Transl Gastroenterol. 2016;7:e183.
   PubMed Web of Science ®Google Scholar
• Rusak E, Chobot A, Krzywicka A, et al. Anti-parietal cell antibodies - diagnostic significance. Adv Med Sci. 2016;61:175–179.
   PubMed Web of Science ®Google Scholar
• Di Sabatino A, Lenti MV, Giuffrida P, et al. New insights into immune mechanisms underlying autoimmune diseases of the gastrointestinal tract. Autoimmun Rev. 2015;14:1161–1169.
   PubMed Web of Science ®Google Scholar
• Lahner E, Brigatti C, Marzinotto I, et al. Luminescent Immunoprecipitation System [LIPS] for detection of autoantibodies against ATP4A and ATP4B Subunits of Gastric Proton Pump H+,K+-ATPase in atrophic body gastritis patients. Clin Transl Gastroenterol. 2017;8:e215.
   PubMed Web of Science ®Google Scholar
• Lahner E, Norman GL, Severi C, et al. Reassessment of intrinsic factor and parietal cell autoantibodies in atrophic gastritis with respect to cobalamin deficiency. Am J Gastroenterol. 2009;104:2071–2079.
   PubMed Web of Science ®Google Scholar
• Lahner E, Carabotti M, Annibale B. Treatment of Helicobacter pylori infection in atrophic gastritis. World J Gastroenterol. 2018;24:2373–2380.
   PubMed Web of Science ®Google Scholar
• Song H, Zhu J, Lu D. Long-term proton pump inhibitor [PPI] use and the development of gastric pre-malignant lesions. Cochrane Database Syst Rev. 2014;12:CD010623.
   PubMed Web of Science ®Google Scholar
• Tosetti C, Stanghellini V, Tucci A, et al. Gastric emptying and dyspeptic symptoms in patients with nonautoimmune fundic atrophic gastritis. Dig Dis Sci. 2000;45:252–257.
   PubMed Web of Science ®Google Scholar
• Kamada T, Haruma K, Hata J, et al. The long-term effect of Helicobacter pylori eradication therapy on symptoms in dyspeptic patients with fundic atrophic gastritis. Aliment Pharmacol Ther. 2003;18:245–252.
   PubMed Web of Science ®Google Scholar
• Yamada S, Tomatsuri N, Kawakami T, et al. Helicobacter pylori eradication therapy ameliorates latent digestive symptoms in chronic atrophic gastritis. Digestion. 2018;97:333–339.
   PubMed Web of Science ®Google Scholar
• IARC Working. Group on the evaluation of carcinogenic risks to humans. schistosomes, liver flukes and Helicobacter pylori: infection with Helicobacter pylori. Monographs on the evaluation of carcinogenic risks to humans. Int Agency Res Cancer. 1994;61:177–240.
   Google Scholar
• Nomura A, Stemmermann GN, Chyou PH, et al. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991;325:1132–1136.
   PubMed Web of Science ®Google Scholar
• Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325:1127–1131.
   PubMed Web of Science ®Google Scholar
• Forman D, Newell DG, Fullerton F, et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ. 1991;302:1302–1305.
   PubMed Web of Science ®Google Scholar
• Rokkas T, Rokka A, Portincasa P. A systematic review and meta-analysis of the role of Helicobacter pylori eradication in preventing gastric cancer. Ann Gastroenterol. 2017;30:414–423.
   PubMed Web of Science ®Google Scholar
• Correa P. Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol. 1995;19 Suppl 1:S37–S43.
   PubMed Web of Science ®Google Scholar
• Ihamaki T, Sipponen P, Varis K, et al. Characteristics of gastric mucosa which precede occurrence of gastric malignancy: results long-term follow-up three family samples. Scand J Gastroenterol. 1991;186(Suppl):16–23.
   Google Scholar
• Van Der Hulst RWM, Van Der Ende A, Dekker FW, et al. Effect of Helicobacter pylori eradication on gastritis in relation to cagA: a prospective 1-year follow-up study. Gastroenterology. 1997;113:25–30.
   PubMed Web of Science ®Google Scholar
• Lahner E, Vaira D, Figura N, et al. Role of noninvasive tests [C-urea breath test and stool antigen test] as additional tools in diagnosis of Helicobacter pylori infection in patients with atrophic body gastritis. Helicobacter. 2004 Oct;9([5]):436–442.
   PubMed Web of Science ®Google Scholar
• Rugge M, Capelle LG, Cappellesso R, et al. Precancerous lesions in the stomach: from biology to clinical patient management. Best Pract Res Clin Gastroenterol. 2013;27:205–223.
   PubMed Web of Science ®Google Scholar
• Song H, Ekheden IG, Zheng Z, et al. Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk western population. BMJ. 2015;351:3967.
   Google Scholar
• Areia M, Dinis-Ribeiro M, Rocha Goncalves F. Cost-utility analysis of endoscopic surveillance of patients with gastric premalignant conditions. Helicobacter. 2014;19:425–436.
   PubMed Web of Science ®Google Scholar
• Lahner E, Hassan C, Esposito G, et al. Cost of detecting neoplasia by surveillance endoscopy in atrophic gastritis in Italy: a low risk country. Digestive Liver Dis. 2017;49:291–296.
   Web of Science ®Google Scholar
• Rugge M, Meggio A, Pravadelli C, et al. Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients. Gut. 2018;68:11–17.
   PubMed Web of Science ®Google Scholar
• Rugge M, Genta RM, Fassan M, et al. OLGA Gastritis Staging for the prediction of gastric cancer risk: a long-term follow-up study of 7436 patients. Am J Gastroenterol. 2018;113:1621–1628.
   PubMed Web of Science ®Google Scholar
• De Vries AC, van Grieken NC, Looman CW, et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology. 2008;134:945–952.
   PubMed Web of Science ®Google Scholar
• Cho SJ, Choi IJ, Kook MC, et al. Staging of intestinal- and diffuse-type gastric cancers with the OLGA and OLGIM staging systems. Aliment Pharmacol Ther. 2013;38:1292–1302.
   PubMed Web of Science ®Google Scholar
• Lahner E, Esposito G, Pilozzi E, et al. Occurrence of gastric cancer and carcinoids in atrophic gastritis during prospective long-term follow up. Scand J Gastroenterol. 2015;50:856–865.
   PubMed Web of Science ®Google Scholar
• Lahner E, Esposito G, Pilozzi E, et al. Gastric cancer in patients with type I gastric carcinoids. Gastric Cancer. 2015;18:564–570.
   PubMed Web of Science ®Google Scholar
• Annibale B, Azzoni C, Corleto VD, et al. Atrophic body gastritis patients with enterochromaffin-like cell dysplasia are at increased risk for the development of type I gastric carcinoid. Eur J Gastroenterol Hepatol. 2001;13:1449–1456.
   PubMed Web of Science ®Google Scholar
• Sato Y, Hashimoto S, Mizuno K, et al. Management of gastric and duodenal neuroendocrine tumors. World J Gastroenterol. 2016;22:6817–6828.
   PubMed Web of Science ®Google Scholar
• Nehme F, Rowe K, Palko W, et al. Autoimmune metaplastic atrophic gastritis and association with neuroendocrine tumors of the stomach. Clin J Gastroenterol. 2019. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Annibale B, Lahner E, Negrini R, et al. Lack of specific association between gastric autoimmunity hallmarks and clinical presentations of atrophic body gastritis. World J Gastroenterol. 2005 Sep 14;11(34):5351–5357.
   PubMed Web of Science ®Google Scholar